Mechanisms of Resistance to Therapies Targeting BRCA-mutant Cancers

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2013 Nov 9

PMID 24202391

Citations 228

Authors

Christopher J Lord

Alan Ashworth

Affiliations

Soon will be listed here.

Abstract

Synthetic lethality provides a potential mechanistic framework for the therapeutic targeting of genetic and functional deficiencies in cancers and is now being explored widely. The first clinical exemplification of synthetic lethality in cancer has been the exploitation of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of cancers with defects in the BRCA1 or BRCA2 tumor suppressor proteins, which are involved in the repair of DNA damage. Although this approach has shown promise, multiple potential resistance mechanisms have been identified. In this Perspective, we discuss these mechanisms and their relevance to the development of selective therapies for BRCA-deficient cancers.

Citing Articles

The Landscape of PARP Inhibitors in Solid Cancers.

Muzzana M, Broggini M, Damia G Onco Targets Ther. 2025; 18:297-317.

PMID: 40051775 PMC: 11884256. DOI: 10.2147/OTT.S499226.

Discovery of novel PARP1/NRP1 dual-targeting inhibitors with strong antitumor potency.

Liu J, Geng Y, Jiang S, Guan L, Gao J, Niu M Front Pharmacol. 2024; 15:1454957.

PMID: 39679370 PMC: 11637875. DOI: 10.3389/fphar.2024.1454957.

Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin-expressing cancers.

Koshrovski-Michael S, Ajamil D, Dey P, Kleiner R, Tevet S, Epshtein Y Sci Adv. 2024; 10(50):eadr4762.

PMID: 39671487 PMC: 11641104. DOI: 10.1126/sciadv.adr4762.

Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models.

Bedia J, Huang Y, Gonzalez A, Gonzalez V, Funingana I, Rahil Z bioRxiv. 2024; .

PMID: 39605494 PMC: 11601625. DOI: 10.1101/2024.11.21.624591.

Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors.

Venkatachalam A, Correia C, Peterson K, Hou X, Schneider P, Strathman A Mol Cancer. 2024; 23(1):224.

PMID: 39375715 PMC: 11457406. DOI: 10.1186/s12943-024-02125-5.

References

Brenner J, Ateeq B, Li Y, Yocum A, Cao Q, Asangani I . Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011; 19(5):664-78. PMC: 3113473. DOI: 10.1016/j.ccr.2011.04.010. View

Brenner J, Feng F, Han S, Patel S, Goyal S, Bou-Maroun L . PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012; 72(7):1608-13. PMC: 3319786. DOI: 10.1158/0008-5472.CAN-11-3648. View

Vilar E, Bartnik C, Stenzel S, Raskin L, Ahn J, Moreno V . MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011; 71(7):2632-42. PMC: 3407272. DOI: 10.1158/0008-5472.CAN-10-1120. View

Dobzhansky T . Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. Genetics. 2010; 31:269-90. PMC: 1209328. DOI: 10.1093/genetics/31.3.269. View

Patel A, Flatten K, Schneider P, Dai N, McDonald J, Poirier G . Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem. 2011; 287(6):4198-210. PMC: 3281688. DOI: 10.1074/jbc.M111.296475. View

Kaelin Jr W . The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005; 5(9):689-98. DOI: 10.1038/nrc1691. View

Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S . BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell. 2011; 20(6):797-809. DOI: 10.1016/j.ccr.2011.11.014. View

Greaves M, Maley C . Clonal evolution in cancer. Nature. 2012; 481(7381):306-13. PMC: 3367003. DOI: 10.1038/nature10762. View

Lord C, Ashworth A . The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-94. DOI: 10.1038/nature10760. View

10.

Hartwell L, Szankasi P, Roberts C, Murray A, Friend S . Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997; 278(5340):1064-8. DOI: 10.1126/science.278.5340.1064. View

11.

Brough R, Frankum J, Sims D, Mackay A, Mendes-Pereira A, Bajrami I . Functional viability profiles of breast cancer. Cancer Discov. 2011; 1(3):260-73. PMC: 3188379. DOI: 10.1158/2159-8290.CD-11-0107. View

12.

Pettitt S, Rehman F, Bajrami I, Brough R, Wallberg F, Kozarewa I . A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One. 2013; 8(4):e61520. PMC: 3636235. DOI: 10.1371/journal.pone.0061520. View

13.

Byers L, Wang J, Nilsson M, Fujimoto J, Saintigny P, Yordy J . Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012; 2(9):798-811. PMC: 3567922. DOI: 10.1158/2159-8290.CD-12-0112. View

14.

Issaeva N, Thomas H, Djureinovic T, Djurenovic T, Jaspers J, Stoimenov I . 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 2010; 70(15):6268-76. PMC: 2913123. DOI: 10.1158/0008-5472.CAN-09-3416. View

15.

Norquist B, Wurz K, Pennil C, Garcia R, Gross J, Sakai W . Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011; 29(22):3008-15. PMC: 3157963. DOI: 10.1200/JCO.2010.34.2980. View

16.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

17.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

18.

McCabe N, Turner N, Lord C, Kluzek K, Bialkowska A, Swift S . Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16):8109-15. DOI: 10.1158/0008-5472.CAN-06-0140. View

19.

Escribano-Diaz C, Orthwein A, Fradet-Turcotte A, Xing M, Young J, Tkac J . A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell. 2013; 49(5):872-83. DOI: 10.1016/j.molcel.2013.01.001. View

20.

Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J . Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle. 2012; 11(20):3837-50. PMC: 3495826. DOI: 10.4161/cc.22026. View